SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-020819
Filing Date
2023-05-11
Accepted
2023-05-11 07:01:28
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-20230511.htm   iXBRL 8-K 55577
2 EX-99.1 agle-ex99_1.htm EX-99 270892
3 GRAPHIC img256443366_0.jpg GRAPHIC 12575
  Complete submission text file 0000950170-23-020819.txt   471172

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT agle-20230511_pre.xml EX-101.PRE 9837
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT agle-20230511_lab.xml EX-101.LAB 13362
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT agle-20230511.xsd EX-101.SCH 2460
8 EXTRACTED XBRL INSTANCE DOCUMENT agle-20230511_htm.xml XML 4716
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 23908746
SIC: 2834 Pharmaceutical Preparations